Reversible protein acetylation provides a central mechanism for controlling gene expression
and cellular signaling events. Two pharmacological inhibitors of protein deacetylation are …

Heart failure, a syndrome culminating the pathogenesis of many forms of heart disease, is
highly prevalent and projected to be increasingly so for years to come. Major efforts are …

Heart failure is a major public health problem in western society. Recently, agents that inhibit
histone deacetylase (HDAC) enzymes were developed and approved by the FDA as …

Approximately five million United States (US) adults are diagnosed with heart failure (HF),
with eight million US adults projected to suffer from HF by 2030. With five-year mortality rates …

Small molecule histone deacetylase (HDAC) inhibitors block adverse cardiac remodeling in
animal models, suggesting unforeseen potential for this class of compounds for the …

Acetylation of histone and nonhistone proteins provides a key mechanism for controlling
signaling and gene expression in heart and kidney. Pharmacological inhibition of protein …

Small molecule histone deacetylase (HDAC) inhibitors block adverse cardiac remodeling in
animal models of heart failure. The efficacious compounds target class I, class IIb and, to a …

Histone deacetylases (HDACs) regulate gene transcription by catalyzing the removal of
acetyl groups from key lysine residues in nucleosomal histones and via the recruitment of …

Reversible histone acetylation is one of the key mechanisms involved in the epigenetic
control of gene expression. A variety of recent studies has revealed a role for acetylation in a …

It has been widely recognized that histone deacetylases (HDAC) are promising targets in the
field of oncology. An impressive body of preclinical research points to the ability of HDAC …